Clinical utility of PD-L1 expression in circulating tumor cells in non-small cell lung cancer patients treated with immunotherapy
- VernacularTitle:循环肿瘤细胞 PD-L1 表达在非小细胞肺癌免疫治疗中的应用
- Author:
Yadong WANG
1
;
Xiaoying YANG
2
,
3
;
Ziqi JIA
2
,
3
;
Zhongxing BING
1
;
Huaxia YANG
4
;
Yanlian YANG
5
;
Zhiyuan HU
5
;
Shanqing LI
1
;
Naixin LIANG
1
Author Information
1. Department of Thoracic Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100730, P.R.China
2. 1. Department of Thoracic Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100730, P.R.China
3. 2. Peking Union Medical College, Eight-Year MD Program, Beijing, 100005, P.R.China
4. Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100730, P.R.China
5. National Center for Nannoscience and Technology, Beijing, 100190, P.R.China
- Publication Type:Journal Article
- Keywords:
Circulating tumor cells;
programmed cell death-ligand 1(PD-L1);
non-small cell lung cancer;
immunotherapy;
review
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2021;28(01):110-115
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the most frequent cancer and the leading cause of cancer death all around the world. Anti-programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) therapies have significantly improved the outcomes of non-small cell lung cancer (NSCLC) patients in recent years. However, the objective response rate in non-screened patients is only about 20%. It is very important to screen out the potential patients suitable for immunotherapy. Immunohistochemical staining of tumor tissue biopsies with PD-L1 antibodies can predict the therapeutic response to immunotherapy to some extent, but it still has some limitations. Recently some clinical studies have shown that PD-L1 expression in circulating tumor cells (CTC-PD-L1) is a potential independent biomarker and may provide important information for immunotherapy in NSCLC. This article will review technology for CTC-PD-L1 detection and the predictive value of CTC-PD-L1 for immunotherapy in NSCLC and review the latest clinical research progress.
